Shield Therapeutics plc

3.20pAs of Sun 8 Nov 2026, 12:00 UTC
LSE:STXHealthcare
Ctry United Kingdom
PE (Fwd) •••
TSR 10Y CAGR (32.50%)
Div yield —
ROE —
Drug Manufacturers (Specialty & Generic)
Beta (5Y) 1.73
PE TTM —
TSR TTM (51.88%)
Mkt cap £34.24M
ROIC (25.22%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
3.52p
9.93%
(66.28%)
Hold 12|12|4|11|4
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.05
0.06
0.06
0.06
22.77%
28.14%
17.42%
21.90%
Revenue$M
1.820
1.911
2.001
1.947
7.86%
8.21%
12.32%
10.53%
Peers (US$44.77M)
Cap (US$)
PE
76.13M
26.51x
29.20M
—
45.46M
—
Capital
TTM
5Y
10Y
Leveragex
0.730
5.735
3.614
EBIT/Intx
1.862
0.475
0.421
Own earn%
(28.88)
52.95
39.04
Sh yield%
13.85
5.57
7.21
Owners
Insiders/Inst%
1.39
54.37
Short interest%
0.77
SBC / revenue%
4.18
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
17
Op margin range%
18–21
$1 testx
—
Incr. ROIC%
3